Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Navidea Biopharmaceuticals Inc
(NY:
NAVB
)
N/A
UNCHANGED
Last Price
Updated: 8:00 PM EDT, Oct 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Navidea Biopharmaceuticals Inc
< Previous
1
2
3
Next >
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
September 15, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
September 01, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees
September 01, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
August 30, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering
August 25, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering
August 18, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results
August 15, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering
August 04, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
August 01, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
August 01, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
July 25, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
July 20, 2022
From
Navidea Biopharmaceuticals, Inc
Via
Business Wire
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
July 05, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
May 24, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
May 23, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
May 12, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update
May 05, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
April 20, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets
April 20, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis
April 19, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
April 18, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
April 12, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
April 12, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs
April 07, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
March 23, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
March 23, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update
March 16, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
February 07, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American
February 03, 2022
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis
December 16, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.